Related Experiment Video

Updated: Jan 19, 2026

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

11.1K

Disappearance of antibodies to HPV 16 E7 after treatment for cervical cancer

J Dillner

    Lancet (London, England)
    |June 19, 1993
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
    10:26

    RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

    Published on: March 11, 2014

    28.1K
    Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
    13:41

    Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

    Published on: March 8, 2012

    12.9K

    Related Experiment Videos

    Last Updated: Jan 19, 2026

    Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
    06:57

    Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

    Published on: June 14, 2019

    11.1K
    RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
    10:26

    RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

    Published on: March 11, 2014

    28.1K
    Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
    13:41

    Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

    Published on: March 8, 2012

    12.9K

    Related Concept Videos

    Cancer Vaccines01:30

    Cancer Vaccines

    976
    Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
    Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
    976
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    3.7K
    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.7K

    Articles linked to this work by shared authors, journal, and citation graph.

    SARS-CoV-2 infections amongst personnel providing home care services for older persons in Stockholm, Sweden.

    Journal of internal medicine·2021

    High-grade cervical intraepithelial neoplasia in human papillomavirus self-sampling of screening non-attenders.

    British journal of cancer·2017

    Molecular methods for identification and characterization of novel papillomaviruses.

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2015

    Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland.

    British journal of cancer·2013

    [Carcinoma of the pararenal gland infiltrating the surrounding tissue and involving the inferior vena cava].

    Aktuelle Urologie·2013

    False-positive prostate cancer markers in a man with symptomatic urethral Chlamydia trachomatis infection.

    International journal of STD & AIDS·2013

    14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan.

    Lancet (London, England)·2026

    Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials.

    Lancet (London, England)·2026

    Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

    Lancet (London, England)·2026

    Endometrial ablation plus levonorgestrel-releasing intrauterine system versus endometrial ablation alone in women with heavy menstrual bleeding in The Netherlands (MIRA2): a multicentre, open-label, randomised, controlled, superiority trial.

    Lancet (London, England)·2026

    Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial.

    Lancet (London, England)·2026

    Time to Treatment Failure as a Recorded Treatment-Process Measure in C-CAT. Reply to Comment on "Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462".

    Current oncology (Toronto, Ont.)·2026

    Does Time to Treatment Failure Measure the Same Clinical Process Across Oncology Facilities? Comment on Kajiura et al. Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462.

    Current oncology (Toronto, Ont.)·2026

    Electroacupuncture Combined with Cognitive Behavioral Therapy for Insomnia Alleviates Insomnia-Anxiety Comorbidity in Gynecological Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial.

    Current oncology (Toronto, Ont.)·2026

    [177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing.

    Current oncology (Toronto, Ont.)·2026

    A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody-Drug Conjugates, and Targeted Therapies.

    Current oncology (Toronto, Ont.)·2026

    A Remotely Delivered Exercise-Based Rehabilitation Program for Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy (EX-CIPN): A Phase I Feasibility Trial.

    Current oncology (Toronto, Ont.)·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us